Anchiano Therapeutics Ltd. - American Depositary Share (ANCN) News
Filter ANCN News Items
ANCN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ANCN News Highlights
- For ANCN, its 30 day story count is now at 1.
- list("500 - Internal server error")
Latest ANCN News From Around the Web
Below are the latest news stories about Anchiano Therapeutics Ltd that investors may wish to consider to help them evaluate ANCN as an investment opportunity.
Anchiano shares rally 76% on Chemomab merger approval, secures $45.5M capital raiseAnchiano Therapeutics (ANCN) soars 76% after-hours as its shareholders voted to approve the contemplated merger with Chemomab and the issuance of Anchiano ADSs in connection with the pending merger.Shareholders also approved a reverse split of ANCN's common shares, expected to take effect immediately prior to the closing of the merger. The combined company is... |
ANCN Stock: 10 Things to Know as Anchiano Therapeutics Rockets HigherANCN stock is an early-stage company engaged in clinical trials for rare liver, lung and skin diseases with no FDA-approved options now. |
ANCHIANO INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Anchiano Therapeutics Ltd. - ANCNFormer Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed merger of Anchiano Therapeutics Ltd. (NasdaqGS: ANCN) with Chemomab Ltd. pursuant to which Anchiano shareholders will end up owning only approximately 10% of the combined company, prior to additional PIPE financing. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company. |
SHAREHOLDER ALERT: WeissLaw LLP Reminds CPAH, CATM, ANCN and GNBF Shareholders About Its Ongoing InvestigationsIf you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: |
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Reminds Investors of Investigations of ANCN, JWS, GXGX, and ALSK MergersWILMINGTON, Del., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating: Anchiano Therapeutics Ltd. (NASDAQ GS: ANCN) regarding possible breaches of fiduciary duties and other violations of law related to Anchiano Therapeutics’ agreement to merge with Chemomab Ltd. To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-anchiano-therapeutics-ltd. Jaws Acquisition Corp. (NYSE: JWS) regarding possible breaches of fiduciary duties and other violations of law related to Jaws Acquisition’s agreement to merge with Cano Health, LLC. To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-jaws-acquisition-corp. GX Acquisition Corp. (NASDAQ GS: GXGX) regarding possible breaches of fiduc... |
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Anchiano Therapeutics Ltd. - ANCNJuan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Anchiano Therapeutics Ltd. ("ANCN" or the "Company") (ANCN) relating to its proposed merger with Chemomab Ltd. Under the terms of the agreement, and before additional PIPE financing, ANCN shareholders are expected to own only 10% of the combined company. |
SHAREHOLDER ALERT: WeissLaw LLP Reminds ANCN, PRVL, WORK, and GNBF Shareholders About Its Ongoing InvestigationsIf you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: |
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Anchiano Therapeutics Ltd. MergerWILMINGTON, Del., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Anchiano Therapeutics Ltd. (“Anchiano”) (NASDAQ CM: ANCN) regarding possible breaches of fiduciary duties and other violations of law related to Anchiano’s agreement to merge with Chemomab Ltd. (“Chemomab”). Under the terms of the agreement, Anchiano will issue a number of American Depository Shares of Anchiano to shareholders of Chemomab. Upon the closing of the merger, shareholders of Chemomab are expected to own approximately 90% of the outstanding shares of Anchiano. To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-anchiano-therapeutics-ltd.You may contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-... |
The Daily Biotech Pulse: Novartis Gets Adcom Backing, Sio Gene Data, 2 IPOs, BioNTech Clinches China Vaccine Supply DealHere's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 15) * Anchiano Therapeutics Ltd - ADR (NASDAQ: ANCN) (announced a reverse merger with Chemomab) * Arvinas Inc (NASDAQ: ARVN) * Beam Therapeutics Inc (NASDAQ: BEAM) * Bioanalytical Systems, Inc. (NASDAQ: BASI) * BioCardia Inc (NASDAQ: BCDA) * BioLineRx ADR Representing 15 Ord Shs (NASDAQ: BLRX) * BioTelemetry Inc (NASDAQ: BEAT) * Chimerix Inc (NASDAQ: CMRX) * Corcept Therapeutics Incorporated (NASDAQ: CORT) * Frequency Therapeutics Inc (NASDAQ: FREQ) * Globus Medical Inc (NYSE: GMED) * Inhibrx Inc (NASDAQ: INBX) * MannKind Corporation (NASDAQ: MNKD) * Ocular Therapeutix Inc (NASDAQ: OCUL) * PRA Health Sciences Inc (NASDAQ: PRAH) * P... |
Anchiano Therapeutics jumps after Chemomab mergerThe merger will create a company focused on advancing Chemomab’s lead product, CM-101, for the treatment of fibrosis-related diseases. |